Research Topics
Species | P C AlbertsenSummaryAffiliation: University of Connecticut Health Center Country: USA Publications
Research Grants
| Collaborators
|
Detail Information
Publications
What is the risk posed by prostate cancer?Peter C Albertsen
University of Connecticut Health Center, 263 Farmington Avenue, Farmington, CT 06030 3955
J Natl Cancer Inst Monogr 2012:169-74. 2012..PSA can estimate tumor volume, but poorly differentiated disease may not produce much PSA. We are unable to predict accurately the risk posed by a specific prostate cancer...
Competing risk analysis of men aged 55 to 74 years at diagnosis managed conservatively for clinically localized prostate cancerP C Albertsen
Division of Urology, University of Connecticut Health Center, Farmington 06030 3955, USA
JAMA 280:975-80. 1998..The appropriate therapy for men with localized prostate cancer is uncertain. Until results of clinical trials are available, men and their physicians need guidance...- Validation of increasing prostate specific antigen as a predictor of prostate cancer death after treatment of localized prostate cancer with surgery or radiationPeter C Albertsen
University of Connecticut Health Center, Farmington, Connecticut 06030 3955, USA
J Urol 171:2221-5. 2004..This study documents patterns of PSA recurrence after surgery or radiation to treat localized prostate cancer and quantifies the extent to which an increasing PSA predicts death from prostate cancer... - Commentary: occult prostate cancer--imposter or the real deal?Peter C Albertsen
University of Connecticut Health Center, Division of Urology, Urology Office, Farmington, CT 06030 2817, USA
Int J Epidemiol 36:281-2. 2007 - 13-year outcomes following treatment for clinically localized prostate cancer in a population based cohortPeter C Albertsen
University of Connecticut Health Center, Farmington 06030 3955, and St Francis Hospital and Medical Center, Hartford, Connecticut, USA
J Urol 177:932-6. 2007.... - 20-year outcomes following conservative management of clinically localized prostate cancerPeter C Albertsen
Division of Urology, University of Connecticut Health Center, Farmington, CT 06030 3955, USA
JAMA 293:2095-101. 2005..The appropriate therapy for men with clinically localized prostate cancer is uncertain. A recent study suggested an increasing prostate cancer mortality rate for men who are alive more than 15 years following diagnosis... - Prostate-specific antigen: how to advise patients as the screening debate continuesPeter C Albertsen
Department of Surgery Urology, University of Connecticut Health Center, Farmington, CT 06030 3955, USA
Cleve Clin J Med 72:521-7. 2005..A possible schedule is to test at age 40, age 45, and every 2 to 3 years from age 50 until about age 75... - Is screening for prostate cancer with prostate specific antigen an appropriate public health measure?Peter C Albertsen
Department of Surgery, University of Connecticut Health Center, Farmington, 06030 3955, USA
Acta Oncol 44:255-64. 2005..The European screening trial and the PLCO trial in the US will hopefully provide some insights into the value of population-based testing... - Prostate cancer and the Will Rogers phenomenonPeter C Albertsen
University of Connecticut Health Center, 263 Farmington Avenue, Farmington, CT 06030 3955, USA
J Natl Cancer Inst 97:1248-53. 2005..To determine whether this decline is in part a result of Gleason score reclassification during the same time period, we documented the potential impact of reclassification between 1992 and 2002 on clinical outcomes... 
The face of high risk prostate cancerPeter C Albertsen
Division of Urology, University of Connecticut Health Center, 263 Farmington Avenue, Farmington, CT 06030 3955, USA
World J Urol 26:205-10. 2008..To define high risk prostate cancer using prostate cancer specific mortality as the key outcome metric...- What is the value of screening for prostate cancer in the US?Peter C Albertsen
Department of Surgery Urology, University of Connecticut Health Center, Farmington, CT 06030 3955, USA
Nat Clin Pract Oncol 2:536-7. 2005 - Should men with low-risk, localized prostate cancer choose active surveillance or undergo a robotic prostatectomy?Peter Albertsen
Division of Urology, University of Connecticut, 263 Farmington Avenue, Farmington, CT 06030, USA
Curr Urol Rep 9:1-2. 2008 - PSA and the conservative treatment of early prostate cancerPeter C Albertsen
Division of Urology, University of Connecticut Health Centre, Farmington 06030 3955, USA
Arch Ital Urol Androl 78:152-3. 2006..Some researchers suggest tracking PSA doubling times as a way of separating those patients with indolent disease from those who are likely to experience progression... - Lower urinary tract symptoms in the older maleKisseng Hsieh
Division of Urology, University of Connecticut Health Center, MC 3955, 263 Farmington Avenue, Farmington, CT 06030 3955, USA
Conn Med 67:487-90. 2003..These combined with a variety of pharmacologic agents (antispasmodics, alpha-antagonists, 5 alpha reductase inhibitors) offer great potential for improving the quality of life of individuals with LUTS... - Should men over the age of 65 years receive PSA screening? Argument againstPeter C Albertsen
Division of Urology, University of Connecticut Health Center, Farmington, CT 06030, USA
Nat Clin Pract Urol 5:232-3. 2008 - When is active surveillance the appropriate treatment for prostate cancer?Peter C Albertsen
University of Connecticut Health Center, 263 Farmington Avenue, Farmington, CT 06030, USA
Acta Oncol 50:120-6. 2011..Furthermore, randomized clinical trials have shown only a modest ten year survival advantage for those men undergoing either surgery or radiation... - The unintended burden of increased prostate cancer detection associated with prostate cancer screening and diagnosisPeter C Albertsen
Division of Urology, University of Connecticut Health Center, Farmington, Connecticut 06030 3955, USA
Urology 75:399-405. 2010.... - Impact of comorbidity on survival among men with localized prostate cancerPeter C Albertsen
Department of Surgery, University of Connecticut Health Center, 263 Farmington Ave, Farmington, CT 06030, USA
J Clin Oncol 29:1335-41. 2011..To provide patients and clinicians more accurate estimates of comorbidity-specific survival stratified by patient age, tumor stage, and tumor grade... - Treatment of localized prostate cancer: when is active surveillance appropriate?Peter C Albertsen
Department of Surgery, University of Connecticut Health Center, 263 Farmington Avenue, Farmington, CT 06030, USA
Nat Rev Clin Oncol 7:394-400. 2010..For men harboring tumors with a Gleason score >7, data from two recently reported Swedish trials suggest lower prostate cancer-related mortality for those men receiving either surgery or radiation... - Bicycle riding and its relationship to the development of erectile dysfunctionJohn A Taylor
Division of Urology, University of Connecticut Health Center, 263 Farmington Avenue, Farmington, CT 06030 3955, USA
J Urol 172:1028-31. 2004..Insufficient data have left cyclists skeptical of this claim. We explore risk factors within cycling that may put riders at risk for the development of erectile dysfunction (ED)... - The effect of micronized estradiol on bone turnover and calciotropic hormones in older men receiving hormonal suppression therapy for prostate cancerPamela Taxel
Division of Endocrinology and Metabolism, University of Connecticut Health Center, 263 Farmington Avenue, Farmington, CT 06030 1317, USA
J Clin Endocrinol Metab 87:4907-13. 2002..We conclude that E(2) inhibits bone resorption in hypogonadal men through a direct skeletal effect that is independent of PTH. Low dose estrogen may be an option for the prevention and/or treatment of bone loss in this population... - Recognition of PSA-derived peptide antigens by T cells from prostate cancer patients without any prior stimulationNitya G Chakraborty
Department of Medicine, University of Connecticut Health Center, 263 Farmington Avenue, Farmington, CT 06030 1315, USA
Cancer Immunol Immunother 52:497-505. 2003.... - Outcomes following active surveillance of men with localized prostate cancer diagnosed in the prostate specific antigen eraBarbara Ercole
Division of Urology, University of Connecticut Health Center, Farmington, Connecticut 06030 3955, USA
J Urol 180:1336-9; discussion 1340-1. 2008..We gained insights concerning outcomes associated with men who elect active surveillance for the management of localized prostate cancer... - The conundrum of prostate cancerPeter C Albertsen
University of Connecticut Health Center, 263 Farmington Avenue, Farmington, Connecticut 06030-3955, USA
Cancer J 8:432-4. 2002 - Expression of vascular endothelial growth factor receptors in human prostate cancerF A Ferrer
Department of Surgery, University of Connecticut Health Center, Farmington 06030 3105, USA
Urology 54:567-72. 1999..Herein, we evaluate the expression of these receptors in ex vivo PCa tissue, benign prostatic hypertrophy (BPH) tissue, and cultured PCa cell lines... - Which results justify the means in prostate cancer treatment?Peter C Albertsen
Department of Surgery, University of Connecticut Health Center, Farmington 06030 3955, USA
Cancer J 8:30-2. 2002 - Populations at high risk for prostate cancerKisseng Hsieh
Division of Urology, Department of Surgery, University of Connecticut Health Center, 263 Farmington Avenue, Farmington, CT 06030-3955, USA
Urol Clin North Am 30:669-76. 2003..Screening men at increased risk of developing prostate cancer appears to be a logical strategy, especially in light of recent reports that suggest a benefit to aggressive treatment... - Use and assessment of PSA in prostate cancerCarl K Gjertson
Division of Urology, University of Connecticut Health Center, 263 Farmington Avenue, Farmington, CT 06030 3955, USA
Med Clin North Am 95:191-200. 2011..In this review, the authors discuss the rationale for prostate cancer screening and present the current guidelines for the use of PSA... - Hierarchical changepoint models for biochemical markers illustrated by tracking postradiotherapy prostate-specific antigen series in men with prostate cancerCarine A Bellera
Department of Clinical Epidemiology and Clinical Research, Institut Bergonie, Regional Comprehensive Cancer Center, Bordeaux, France
Ann Epidemiol 18:270-82. 2008.... - Survival following primary androgen deprivation therapy among men with localized prostate cancerGrace L Lu-Yao
Department of Environmental and Occupational Medicine, Robert Wood Johnson Medical School, New Brunswick, NJ 08901, USA
JAMA 300:173-81. 2008..Despite a lack of data, increasing numbers of patients are receiving primary androgen deprivation therapy (PADT) as an alternative to surgery, radiation, or conservative management for the treatment of localized prostate cancer... - Prostate-cancer mortality in the USA and UK in 1975-2004: an ecological studySimon M Collin
Department of Social Medicine, University of Bristol, Canynge Hall, Bristol, UK
Lancet Oncol 9:445-52. 2008..Our aim was to study trends over time in prostate-cancer mortality and incidence in the USA and UK in 1975-2004, and compare these patterns with trends in screening and treatment... - Active surveillance for early-stage prostate cancer: review of the current literatureMarc A Dall'Era
Department of Urology, University of California at San Francisco Comprehensive Cancer Center, University of California at San Francisco, San Francisco, California 94143 1695, USA
Cancer 112:1650-9. 2008..The best candidates for active surveillance are being defined, as are predictors of active treatment. The psychosocial ramifications of surveillance for prostate cancer can be profound and future needs and unmet goals will be discussed... - Detecting trends in noisy data series: application to biomarker seriesCarine A Bellera
Department of Clinical Epidemiology and Clinical Research, Institut Bergonie, Regional Comprehensive Cancer Center, Bordeaux, France
Am J Epidemiol 167:1130-9. 2008..The method is particularly flexible and could be applied to evaluate other rules that purport to accurately detect upturns (downturns) in other noisy data series, including other medical data or other application areas... - Natural experiment examining impact of aggressive screening and treatment on prostate cancer mortality in two fixed cohorts from Seattle area and ConnecticutGrace Lu-Yao
HealthStat, Princeton, NJ 08543, USA
BMJ 325:740. 2002.... - The prostate cancer conundrumPeter C Albertsen
J Natl Cancer Inst 95:930-1. 2003 - Race independently predicts prostate specific antigen testing frequency following a prostate carcinoma diagnosisSteven B Zeliadt
Fred Hutchinson Cancer Research Center, Seattle, Washington 98109-1024, USA
Cancer 98:496-503. 2003..Further research is needed to identify the reasons for the racial disparity in PSA surveillance and to design interventions to lessen these differences... - Racial/Ethnic differences in functional outcomes in the 5 years after diagnosis of localized prostate cancerTerri Kang Johnson
University of Southern California Keck School of Medicine, Dept of Preventive Medicine, 1441 Eastlake Ave, Rm 3427A, MC9175, Los Angeles, CA 90089 9175, USA
J Clin Oncol 22:4193-201. 2004..We investigated racial/ethnic differences in functional outcomes up to 5 years after diagnosis among men with aggressively treated localized prostate cancer... - General quality of life 2 years following treatment for prostate cancer: what influences outcomes? Results from the prostate cancer outcomes studyDavid F Penson
Section of Urology, VA Puget Sound Health Care System and the Department of Urology, University of Washington, Seattle, WA 98108, USA
J Clin Oncol 21:1147-54. 2003..The goal of this study was to determine the relationship between primary treatment, urinary dysfunction, sexual dysfunction, and general health-related quality of life (HRQOL) in prostate cancer... - Clinical and physical determinants for toxicity of 125-I seed prostate brachytherapyPeter C Albertsen
J Urol 174:1969-70. 2005 - Facing erectile dysfunction due to prostate cancer treatment: perspectives of men and their partnersPeter C Albertsen
J Urol 174:1969. 2005 - United States radiation oncologists' and urologists' opinions about screening and treatment of prostate cancer vary by regionMary McNaughton Collins
Medical Practices Evaluation Center, Massachusetts General Hospital, Boston, Massachusetts 02114, USA
Urology 60:628-33. 2002..Whether the distinctive style of prostate cancer diagnosis and treatment in Florida results in improved outcomes has yet to be proved... - PSA testing: public policy or private penchant?Peter C Albertsen
JAMA 296:2371-3. 2006 - 5-year urinary and sexual outcomes after radical prostatectomy: results from the prostate cancer outcomes studyDavid F Penson
Department of Urology, Keck School of Medicine, University of Southern California, Los Angeles, California 90089, USA
J Urol 173:1701-5. 2005..In this study we assessed temporal changes in urinary and sexual function up to 5 years following radical prostatectomy in a population based cohort... - Systematic review and meta-analysis of monotherapy compared with combined androgen blockade for patients with advanced prostate carcinomaDavid J Samson
Technology Evaluation Center, Blue Cross and Blue Shield Association, Washington, DC 20005, USA
Cancer 95:361-76. 2002..Outcomes of interest included overall, cancer specific, and progression-free survival; time to treatment failure; adverse events; and quality of life... - Lessons learnt about early prostate cancer from large scale databases: population-based pearls of wisdomDavid F Penson
University of Washington, Seattle, WA 98106, USA
Surg Oncol 11:3-11. 2002..Information gathered from large, administrative databases will be helpful when counseling patients regarding their treatments options for localized prostate cancer and in identifying future directions for prostate cancer research... - Patient outcomes and length of hospital stay after radical prostatectomy for prostate cancer: analysis of hospital episodes statistics for EnglandAndrew Judge
MRC Health Services Research Collaboration, Department of Social Medicine, University of Bristol, Bristol, UK
BJU Int 100:1040-9. 2007.... - General versus spinal anesthesia in patients undergoing radical retropubic prostatectomy: results of a prospective, randomized studyPeter C Albertsen
J Urol 174:931. 2005 - A charting tool for estimating the PSA doubling time in patients with prostate cancerCarine A Bellera
Int J Radiat Oncol Biol Phys 66:315-6. 2006 - Outcomes of treatment vs observation of localized prostate cancer in elderly menGrace L Lu-Yao
JAMA 297:1651; author reply 1652-3. 2007 - Competing risks for patients with localized prostate cancerJerome Seidenfeld
J Natl Cancer Inst 99:1498-9. 2007 - Quality of life following localized prostate cancer treated initially with androgen deprivation therapy or no therapyArnold L Potosky
Division of Cancer Control and Population Sciences, National Cancer Institute, Bethesda, MD
J Natl Cancer Inst 94:430-7. 2002..Therefore, men considering ADT as an initial treatment should be aware that sexual function and some aspects of physical well-being are likely to be affected in the first year following this treatment...
Research Grants
- COMPARISON OF TREATMENT EFFICACY FOR PROSTATE CANCERPeter Albertsen; Fiscal Year: 2002....